Health Care [ 10/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases.
It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134.
The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 25 | -0.19 Increased by +46.42% | - |
| May 13, 25 | -0.95 Decreased by -105.79% | - |
| Mar 28, 25 | 3.63 Increased by +522.09% | -8.00 Increased by +145.38% |
| Nov 8, 24 | -2.00 Decreased by -42.86% | -6.50 Increased by +69.23% |
| Aug 13, 24 | -0.35 Increased by +82.27% | -0.14 Decreased by -153.29% |
| May 15, 24 | -0.46 Increased by +77.61% | -0.87 Increased by +46.98% |
| Mar 11, 24 | -0.86 Increased by +68.15% | -1.33 Increased by +35.34% |
| Nov 14, 23 | -1.40 Decreased by -677.78% | -1.27 Decreased by -10.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -762.00 K Increased by +90.71% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -153.00 K Increased by +97.05% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.99 M Decreased by -30.88% | -952.00 K Increased by +88.95% | Decreased by -47.79% Increased by +84.01% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -1.41 M Increased by +85.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.20 M Increased by +49.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.19 M Increased by +71.54% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.88 M Increased by +N/A% | -8.62 M Increased by +58.68% | Decreased by -298.96% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.06 M Increased by +47.05% | Decreased by N/A% Decreased by N/A% |